Esther Martinborough
Directeur/Membre du Conseil chez CODEXIS, INC.
Fortune : 153 522 $ au 30/04/2024
Profil
Esther Martinborough is an Independent Director at Codexis, Inc. since 2021.
She is also the Chief Scientific Officer at Escient Pharmaceuticals, Inc. since 2018.
Prior to her current positions, she worked as the Executive Director-Research at Receptos LLC from 2008 to 2018.
Dr. Martinborough holds a doctorate degree from the Swiss Federal Institute of Technology and a graduate degree from the University of California.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CODEXIS, INC.
0,08% | 18/04/2024 | 57 933 ( 0,08% ) | 153 522 $ | 30/04/2024 |
Postes actifs de Esther Martinborough
| Sociétés | Poste | Début |
|---|---|---|
| CODEXIS, INC. | Directeur/Membre du Conseil | 02/02/2021 |
Escient Pharmaceuticals, Inc.
 Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA. | Directeur Technique/Scientifique/R&D | 01/04/2023 |
Anciens postes connus de Esther Martinborough
| Sociétés | Poste | Fin |
|---|---|---|
| RECEPTOS INC | Directeur/Membre du Conseil | 01/01/2015 |
Formation de Esther Martinborough
| Swiss Federal Institute of Technology | Doctorate Degree |
| University of California | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CODEXIS, INC. | Process Industries |
| Entreprise privées | 2 |
|---|---|
Escient Pharmaceuticals, Inc.
Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA. | Health Technology |
Receptos LLC
 Receptos LLC Pharmaceuticals: MajorHealth Technology Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA. | Health Technology |